Target intelligence / Profile preview

Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)

Target
MAP4K1
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase
01

Overview

Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1), commonly known as Hematopoietic progenitor kinase 1 (HPK1), is a serine/threonine kinase predominantly expressed in hematopoietic cells, including T cells, B cells, and dendritic cells. It acts as a critical negative regulator of T-cell receptor (TCR) signaling by phosphorylating the adaptor protein SLP-76, which leads to its ubiquitination and degradation, thereby dampening T-cell activation, proliferation, and cytokine production. In the tumor microenvironment, HPK1 is chronically activated, contributing to T-cell exhaustion and allowing tumors to evade immune surveillance. Consequently, HPK1 has emerged as a highly attractive therapeutic target in immuno-oncology. Pharmacological inhibition or degradation of HPK1 using small molecules or PROTACs enhances anti-tumor immune responses, particularly when combined with immune checkpoint inhibitors like PD-1/PD-L1 antibodies. However, drug development faces challenges such as achieving selectivity over other MAP4K family members to avoid off-target toxicities, managing potential immune-related adverse events from systemic immune activation, and addressing the scaffolding functions of the protein.

Other names
Hematopoietic progenitor kinase 1HPK1MAPK/ERK kinase kinase kinase 1MEK kinase kinase 1MEKKK 1
02

Mechanism of action

Inhibition of kinase activity to prevent phosphorylation of SLP-76 and restore T-cell activation, or targeted protein degradation (PROTAC) to eliminate both kinase and scaffolding functions.

03

Biological functions

Signal transductionImmune responseApoptosisT-cell receptor signalingNegative regulation of T-cell activation
04

Disease associations

CancerInflammationAutoimmune disease
05

Safety considerations

Immune-related adverse events (irAEs) such as colitis, hepatitis, and pneumonitisOff-target kinase inhibition (e.g., GLK/MAP4K3, ROCK2 causing cardiovascular toxicity)Cytokine release syndrome (CRS) or hyper-inflammatory responsesGastrointestinal toxicities (nausea, diarrhea, vomiting)Anemia and fatigue
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

Phosphorylated SLP-76 (pSLP-76)Interleukin-2 (IL-2) secretionInterferon-gamma (IFN-gamma) secretionT-cell infiltration score

Beyond the preview

Go deeper on Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call